NSE - Delayed Quote INR

Zydus Lifesciences Limited (ZYDUSLIFE.NS)

973.65
+13.50
+(1.41%)
At close: 3:29:55 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
225,738,000
225,738,000
190,215,000
168,778,000
148,276,000
Cost of Revenue
63,380,000
63,380,000
62,282,000
65,589,000
58,189,000
Gross Profit
162,358,000
162,358,000
127,933,000
103,189,000
90,087,000
Operating Expense
102,565,000
102,565,000
82,541,000
74,640,000
65,320,000
Operating Income
59,793,000
59,793,000
45,392,000
28,549,000
24,767,000
Net Non Operating Interest Income Expense
-1,659,000
-1,659,000
-812,000
-541,000
-511,000
Pretax Income
60,267,000
60,267,000
48,089,000
25,897,000
28,381,000
Tax Provision
14,119,000
14,119,000
9,775,000
5,878,000
5,117,000
Net Income Common Stockholders
45,255,000
45,255,000
38,595,000
19,603,000
44,873,000
Diluted NI Available to Com Stockholders
45,255,000
45,255,000
38,595,000
19,603,000
44,873,000
Basic EPS
45.03
44.97
38.14
19.30
43.83
Diluted EPS
45.03
44.97
38.14
19.30
43.83
Basic Average Shares
1,007,430.48
1,006,337.56
1,011,929.73
1,015,649.87
1,023,742.60
Diluted Average Shares
1,007,430.48
1,006,337.56
1,011,929.73
1,015,649.87
1,023,742.60
Rent Expense Supplemental
--
--
261,000
229,000
206,000
Total Expenses
165,945,000
165,945,000
144,823,000
140,229,000
123,509,000
Net Income from Continuing & Discontinued Operation
45,255,000
45,255,000
38,595,000
19,603,000
44,873,000
Normalized Income
48,286,533.97
48,286,533.97
38,478,135.81
29,455,892.54
20,281,492.55
Interest Income
--
--
1,268,000
757,000
688,000
Interest Expense
1,659,000
1,659,000
812,000
1,255,000
1,144,000
Net Interest Income
-1,659,000
-1,659,000
-812,000
-541,000
-511,000
EBIT
61,926,000
61,926,000
48,901,000
27,152,000
29,525,000
EBITDA
71,084,000
71,084,000
56,542,000
34,379,000
36,886,000
Reconciled Cost of Revenue
63,380,000
63,380,000
62,282,000
65,589,000
58,189,000
Reconciled Depreciation
9,158,000
9,158,000
7,641,000
7,227,000
7,361,000
Net Income from Continuing Operation Net Minority Interest
45,255,000
45,255,000
38,365,000
19,649,000
22,416,000
Total Unusual Items Excluding Goodwill
-2,196,000
-2,196,000
-142,000
-5,001,000
2,604,000
Total Unusual Items
-846,000
-846,000
-142,000
940,000
2,604,000
Normalized EBITDA
71,930,000
71,930,000
56,684,000
33,439,000
34,282,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-514,466.03
-514,466.03
-28,864.19
-1,135,107.46
469,492.55
3/31/2022 - 4/27/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NATCOPHARM.NS NATCO Pharma Limited
863.10
+0.56%
 
DRREDDY.NS Dr. Reddy's Laboratories Limited
1,319.10
-0.14%
 
CIPLA.NS Cipla Limited
1,506.60
+0.16%
 
LUPIN.NS Lupin Limited
1,994.60
-0.25%
 
SUNPHARMA.NS Sun Pharmaceutical Industries Limited
1,694.40
+0.91%
 
MANKIND.NS Mankind Pharma Limited
2,356.70
+0.18%
 
ASTRAZEN.NS AstraZeneca Pharma India Limited
10,057.00
+2.73%
 
AUROPHARMA.NS Aurobindo Pharma Limited
1,161.10
0.00%
 
GLENMARK.NS Glenmark Pharmaceuticals Limited
1,599.20
+0.57%
 
TORNTPHARM.NS Torrent Pharmaceuticals Limited
3,180.70
+0.84%